0001753926-24-001628.txt : 20240926 0001753926-24-001628.hdr.sgml : 20240926 20240926084600 ACCESSION NUMBER: 0001753926-24-001628 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20240926 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240926 DATE AS OF CHANGE: 20240926 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Vivani Medical, Inc. CENTRAL INDEX KEY: 0001266806 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 000000000 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36747 FILM NUMBER: 241326252 BUSINESS ADDRESS: STREET 1: 1350 S. LOOP ROAD CITY: ALAMEDA STATE: CA ZIP: 94502 BUSINESS PHONE: 818-833-5000 MAIL ADDRESS: STREET 1: 1350 S. LOOP ROAD CITY: ALAMEDA STATE: CA ZIP: 94502 FORMER COMPANY: FORMER CONFORMED NAME: SECOND SIGHT MEDICAL PRODUCTS INC DATE OF NAME CHANGE: 20031010 8-K 1 vani-20240926.htm 8-K vani-20240926.htm
0001266806 false 0001266806 2024-09-26 2024-09-26
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 26, 2024


 

 

Vivani Medical, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

 

 

 

 

 

 

Delaware

 

001-36747

 

02-0692322

(State or Other Jurisdiction of Incorporation)

 

(Commission File Number)

 

(IRS Employer Identification No.)

 

1350 S. Loop Road

Alameda, California 94502

(Address of principal executive offices, including zip code)

 

(415) 506-8462

(Telephone number, including area code, of agent for service)

 

(Former name or former address, if changed since last report.)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

 ☐

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

 

 ☐

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

 

 ☐

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

 

 ☐

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 Securities registered pursuant to Section 12(b) of the Act:

 

 

 

 

 

 

Title of each class

 

Trading
Symbol(s)

 

Name of each exchange on which registered

Common Stock, par value $0.0001 per share

 

VANI

 

Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

 

On September 26, 2024, Vivani Medical, Inc. (the “Company”) announced it received regulatory approval to initiate a first in human clinical trial, known as the LIBERATE-1™, with the Company’s GLP-1 (exenatide) implant in obese and overweight individuals in Australia. A copy of the press release issued in connection with this announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.

 

Item 9.01

Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit
No.

 

Description

 

 

 

99.1

 

Press release issued by Vivani Medical, Inc. on September 26, 2024.

 

 

 

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

VIVANI MEDICAL, INC.

 

 

 

Date: September 26, 2024

By:

/s/ Donald Dwyer

 

Name:

Donald Dwyer

 

Title:

Chief Business Officer

 

 

 EX-101.DEF 2 vani-20240926_def.xml DEFINITION EX-101.PRE 3 vani-20240926_pre.xml PRESENTATION EX-101.CAL 4 vani-20240926_cal.xml CALCULATION EX-101.LAB 5 vani-20240926_lab.xml LABEL Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.SCH 6 vani-20240926.xsd SCHEMA 00000001 - Document - Cover link:presentationLink link:definitionLink link:calculationLink EX-99.1 7 ex991_1.htm EXHIBIT 99.1

Exhibit 99.1


FOR IMMEDIATE RELEASE

 

Vivani Medical Receives Regulatory Approval to Initiate First in Human
Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in Australia

 

 

NPM-115 clinical program utilizes a miniature, GLP-1 (exenatide) implant designed to provide comparable efficacy to semaglutide, the active ingredient in Ozempic®/Wegovy®, with twice- yearly administration

 

Study will represent the first clinical application of NanoPortal™, the Company’s proprietary drug implant platform technology

 

ALAMEDA, Calif., September 26, 2024 -- (BUSINESS WIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative, biopharmaceutical company developing novel, ultra long-acting drug implants, today announced that the Bellberry Human Research Ethics Committee (“HREC”) has approved and the Therapeutic Goods Administration (“TGA”) in Australia has formally acknowledged a first in human clinical trial of the Company’s miniature, subdermal GLP-1 (exenatide) implant in obese and overweight subjects. This clinical trial, known as LIBERATE-1™, will investigate the safety, tolerability and full pharmacokinetic
profile of an exenatide implant and represents the first clinical application of the Company’s proprietary NanoPortal™ drug implant technology.

 

“Securing regulatory approval keeps us on schedule to initiate this trial in Australia in the fourth quarter of 2024,” said Adam Mendelsohn, Ph.D., Vivani President and Chief Executive Officer. “Preclinical weight loss and liver fat data announced earlier this year supports the potential for our GLP-1 implant to provide comparable efficacy to semaglutide, the active ingredient in blockbuster products Ozempic® and Wegovy®, but with the significant benefit of twice-yearly administration. We remain confident that our emerging portfolio of miniature, ultra long-acting, GLP-1 implants has the potential to be highly differentiated from the injectable and oral products in the market and in development. Specifically, our implants are uniquely designed to address medication non-adherence, a critical challenge for many patients which we believe represents the largest opportunity to improve real world health outcomes for patients, and the steady delivery of medicine enabled by our NanoPortal technology may also improve treatment tolerability.”


LIBERATE-1 will be a randomized investigation of the safety, tolerability and pharmacokinetic profile of the exenatide NanoPortal implant in obese or overweight subjects. The trial will enroll participants who will be titrated on weekly semaglutide injections for 8 weeks (0.25 mg/week for 4 weeks followed by 0.5 mg/week for 4 weeks) before being randomized to receive a single administration of Vivani’s exenatide implant (n=8), weekly exenatide injections (n=8), or weekly 1 mg semaglutide injections (n=8) for a 9-week treatment duration. Changes in weight will be measured. The trial is expected to be initiated later this year with data projected to be available in 2025.


If available, Vivani intends to utilize research and development incentives and rebates from the Australian government in order to defray a portion of the costs from the trial. Since clinical studies conducted in Australia comply with the International Conference on Harmonization guidelines and data generated in Australia generally are acceptable to the U.S. Food and Drug Administration and other regulatory authorities, Vivani anticipates use of relevant clinical data generated in Australia to support regulatory submissions in other geographies including the United States. Additional guidance regarding future regulatory submissions will be provided as new information becomes available.


Ozempic® and Wegovy® are registered trademarks of Novo Nordisk A/S.

 

About Vivani Medical, Inc.

 

Leveraging its proprietary NanoPortal TM platform, Vivani develops biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence, and potentially to improve patient tolerance to their medication. Vivani’s lead program, NPM-115, utilizes a miniature, six-month, subdermal, GLP-1 (exenatide) implant under development for the treatment of chronic weight management in obese or overweight individuals. Vivani’s emerging pipeline also includes the NPM-139 (semaglutide) implant which is also under development for chronic weight management in obese and overweight individuals. The semaglutide implant has the added potential benefit of once-yearly administration. NPM-119 refers to the Company’s Type 2 Diabetes development program utilizing a six-month, subdermal exenatide implant. Both the NPM-115 and NPM-119 programs utilize exenatide based products with a higher-dose associated with the NPM-115 program for chronic weight management in obese or overweight patients. These NanoPortal implants are designed to provide patients with the opportunity to realize the full potential benefit of their medication by avoiding the challenges associated with the daily or weekly administration of orals and injectables. Medication non-adherence occurs when patients do not take their medication as prescribed. This affects an alarming number of patients, approximately 50%, including those taking daily pills. Medication non-adherence, which contributes to more than $500 billion in annual avoidable healthcare costs and 125,000 potentially preventable deaths annually in the U.S. alone, is a primary and daunting reason obese or overweight patients, and patients taking type 2 diabetes or other chronic disease treatments, face significant challenges in achieving positive real-world effectiveness. While the current GLP-1 landscape includes over 50 new molecular entities under clinical stage development, Vivani remains confident that its highly differentiated portfolio of miniature long-acting GLP-1 implants have the potential to provide an attractive therapeutic option for patients, prescribers and payers.




Forward-Looking Statements


This press release contains certain “forward-looking statements” within the meaning of the “safe harbor” provisions of the US Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “target,” “believe,” “expect,” “will,” “may,” “anticipate,” “estimate,” “would,” “positioned,” “future,” and other similar expressions that in this press release, including statements regarding Vivani’s business, products in development, including the therapeutic potential thereof, the planned development therefor, the initiation of the LIBERATE-1 trial and reporting of trial results, Vivani’s emerging development plans for NPM-115, NPM-139, or Vivani’s plans with respect to Vivani’s technology, strategy, cash position and financial runway. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on Vivani’s current beliefs, expectations, and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of Vivani’s control. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause actual results and outcomes to differ materially from those indicated in the forward-looking statements include, among others, risks related to the development and commercialization of Vivani’s products, including NPM-115 and NPM-119; delays and changes in the development of Vivani’s products, including as a result of applicable laws, regulations and guidelines, potential delays in submitting and receiving regulatory clearance or approval to conduct Vivani’s development activities, risks related to the initiation, enrollment and conduct of Vivani’s planned clinical trials and the results therefrom; Vivani’s history of losses and Vivani’s ability to access additional capital or otherwise fund Vivani’s business. There may be additional risks that the Company considers immaterial, or which are unknown. A further list and description of risks and uncertainties can be found in the Company’s most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission filed on March 26, 2024, as updated by the Company’s subsequent Quarterly Reports on Form 10-Q. Any forward-looking statement made by Vivani in this press release is based only on information currently available to the Company and speaks only as of the date on which it is made. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of added information, future developments or otherwise, except as required by law.


Company Contact:
Donald Dwyer
Chief Business Officer
info@vivani.com
(415) 506-8462


Investor Relations Contact:
Jami Taylor
Investor Relations Advisor
investors@vivani.com
(415) 506-8462


Media Contact:
Sean Leous
ICR Westwicke
sean.leous@westwicke.com
(646) 866-4012



 XML 9 R1.htm IDEA: XBRL DOCUMENT v3.24.3
Cover
Sep. 26, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Sep. 26, 2024
Entity File Number 001-36747
Entity Registrant Name Vivani Medical, Inc.
Entity Central Index Key 0001266806
Entity Tax Identification Number 02-0692322
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 1350 S. Loop Road
Entity Address, City or Town Alameda
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94502
City Area Code (415)
Local Phone Number 506-8462
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol VANI
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html 1 22 1 false 0 0 false 0 false false R1.htm 00000001 - Document - Cover Sheet http://vivani.com/role/Cover Cover Cover 1 false false All Reports Book All Reports vani-20240926.htm vani-20240926.xsd vani-20240926_cal.xml vani-20240926_def.xml vani-20240926_lab.xml vani-20240926_pre.xml http://xbrl.sec.gov/dei/2024 true true JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "vani-20240926.htm": { "nsprefix": "vani", "nsuri": "http://vivani.com/20240926", "dts": { "inline": { "local": [ "vani-20240926.htm" ] }, "schema": { "local": [ "vani-20240926.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd" ] }, "calculationLink": { "local": [ "vani-20240926_cal.xml" ] }, "definitionLink": { "local": [ "vani-20240926_def.xml" ] }, "labelLink": { "local": [ "vani-20240926_lab.xml" ] }, "presentationLink": { "local": [ "vani-20240926_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2024": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2024": 22 }, "report": { "R1": { "role": "http://vivani.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "D20240926", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "vani-20240926.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20240926", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "vani-20240926.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentDescription", "presentation": [ "http://vivani.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://vivani.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AnnualInformationForm", "presentation": [ "http://vivani.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://vivani.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://vivani.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CountryRegion", "presentation": [ "http://vivani.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://vivani.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAccountingStandard", "presentation": [ "http://vivani.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": [ "http://vivani.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://vivani.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://vivani.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://vivani.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodStartDate", "presentation": [ "http://vivani.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://vivani.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentRegistrationStatement", "presentation": [ "http://vivani.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://vivani.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyReport", "presentation": [ "http://vivani.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://vivani.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://vivani.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://vivani.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://vivani.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://vivani.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine3", "presentation": [ "http://vivani.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://vivani.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": [ "http://vivani.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://vivani.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://vivani.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://vivani.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://vivani.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://vivani.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://vivani.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://vivani.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": [ "http://vivani.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://vivani.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://vivani.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://vivani.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://vivani.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPrimarySicNumber", "presentation": [ "http://vivani.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://vivani.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://vivani.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://vivani.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://vivani.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://vivani.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": [ "http://vivani.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://vivani.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Extension", "presentation": [ "http://vivani.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://vivani.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoTradingSymbolFlag", "presentation": [ "http://vivani.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://vivani.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://vivani.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://vivani.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://vivani.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12gTitle", "presentation": [ "http://vivani.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://vivani.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityReportingObligation", "presentation": [ "http://vivani.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://vivani.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://vivani.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://vivani.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 17 0001753926-24-001628-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001753926-24-001628-xbrl.zip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end XML 18 vani-20240926_htm.xml IDEA: XBRL DOCUMENT 0001266806 2024-09-26 2024-09-26 0001266806 false 8-K 2024-09-26 Vivani Medical, Inc. DE 001-36747 02-0692322 1350 S. Loop Road Alameda CA 94502 (415) 506-8462 false false false false Common Stock, par value $0.0001 per share VANI NASDAQ false